Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Jonathan Rosenberg MD

Jonathan Rosenberg MD

Chief, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center; Attending Physician, Memorial Hospital, Memorial Sloan Kettering Cancer Center; Professor of Medicine, Weill Cornell Medical College, New York, New York

Jonathan Rosenberg, MD, is the Chief of the Genitourinary Oncology Service at the Memorial Sloan Kettering Cancer Center (MSKCC), Attending Physician at Memorial Hospital at MSKCC, and Professor of Medicine at Weill Cornell Medical College.  He holds the Enno W. Ercklentz Chair in Genitourinary Oncology.

Dr. Rosenberg completed his internship and residency in internal medicine at New York Presbyterian Hospital-Cornell Medical Center and Hematology/Oncology Fellowship at UCSF. He previously served on the faculty at UCSF Comprehensive Cancer Center and the Dana-Farber Cancer Institute prior to coming to MSKCC. Dr. Rosenberg’s research focuses on understanding bladder cancer biology with the goal of developing new therapeutic approaches in bladder cancer.

Disclosures

Dr. Rosenberg reports the following:

Type of disclosure then companies

Comments:

Grants

 

Roche/Genentech, AstraZeneca, Seagen/Pfizer, Astellas, Acrivon, Loxo at Lilly; Bayer;

Trial funding

 

 

Consulting fees

 

Aadi Bioscience; Alligator Bioscience; Astellas; AstraZeneca; Aktis; Bayer; BMS; Boehringer Ingelheim; Century Therapeutics; EMD Serono; Generate Biomedicines; Gilead; IMVAX; Janssen Oncology; Loxo at Lilly; Merck; Roche/ Genentech; Samsung Bioepis; Seagen/Pfizer; Tyra Biosciences

Consulting fees

Kalivir;

Uncompensated

 

 

Honoraria

 

EMD-Serono, Pfizer; RTP, Medscape, MJH Life Sciences, Clinical Care Options, Mashup Media, Clinical Education Alliance; PSL; Touch Oncology; Up To Date; Medistrava; Ideology Health

 

 

 

Support for attending meetings and/or travel

 

Seagen

Travel to ESMO to present trial

 

 

Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid

 

Alliance for Clinical Trials in Oncology

Co-Chair, Genitourinary Committee

Recent Contributions to PracticeUpdate:

  1. Perioperative Durvalumab With Neoadjuvant Chemotherapy for Operable Bladder Cancer

Most Read This Week

Recently Updated